XORTX Therapeutics Announces New Private Placement Initiative
XORTX Therapeutics Inc. (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a leading player in developing innovative therapies for progressive kidney disease and gout, recently unveiled plans for a non-brokered private placement aimed at raising USD $3 million. This initiative is set to involve the issuance of approximately 3,409,090 common share units at a price of USD $0.88 each. Each unit will consist of one common share along with an accompanying share purchase warrant that can be exercised for another common share at a price of USD $1.20 per share, for a period extending over the next five years.
Details of the Offering
The structure of the offering is designed to not only raise funds but also provide an attractive opportunity for investors to enhance their stake in the company. If the stock price of XORTX exceeds USD $2.00 for ten consecutive trading days, the company can accelerate the expiry of the warrants to a 30-day timeframe following notice to warrant holders.
Utilization of Funds
The net proceeds from this offering are earmarked for advancing XORTX’s innovative product pipeline, particularly in their efforts aimed at treating gout, while also providing general working capital. The company’s ongoing projects demonstrate a commitment to enhancing healthcare solutions for chronic conditions.
About XORTX’s Innovative Programs
XORTX is focused on several groundbreaking products in its development pipeline. These include:
- XRx-026: Targeting treatment for gout.
- XRx-008: A program dedicated to ADPKD (autosomal dominant polycystic kidney disease).
- XRx-101: Designed for treating acute kidney injury and related conditions caused by respiratory viruses.
- XRx-225: A pre-clinical program aimed at addressing Type 2 diabetic nephropathy.
The company aims to significantly lower uric acid production through targeted therapies that address the underlying issues related to purine metabolism and xanthine oxidase activity. With a focus on improving patient outcomes, XORTX is leading the charge in developing effective treatments for these prevalent health challenges.
Regulatory Approval and Compliance
The offering will proceed contingent upon approval from the TSX Venture Exchange. Moreover, all applicable securities regulations will be observed to ensure compliance during the share issuance process. Investors should note that shares acquired will be subject to a hold period, aligning with Canadian securities legislation.
Corporate Contact Information
For further inquiries about the offering or the company’s ongoing projects, interested parties can reach out to:
Allen Davidoff, CEO
Email: adavidoff@xortx.com | Phone: +1 403 455 7727
Nick Rigopulos, Director of Communications
Email: nick@alpineequityadv.com | Phone: +1 617 901 0785
Frequently Asked Questions
What is the purpose of the USD $3 million offering by XORTX?
The funds will be used to advance XORTX's programs targeting gout and for general working capital.
How many common share units will be issued in the offering?
Up to 3,409,090 common share units are expected to be issued at a price of USD $0.88 each.
Who can participate in the offering?
This private placement is non-brokered, primarily aimed at accredited investors and others who meet specific eligibility criteria.
What happens to the issued shares after the offering?
The issued shares will be subject to a four month and one day hold period as per Canadian securities regulations.
What is the significance of the warrants included in the offering?
Warrants provide investors an opportunity to purchase additional shares at a set price, potentially increasing their investment's value as the company grows.
